Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy-Reference-Cited by-同舟云学术

Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy

Published:2023-10 Issue:10 Volume:31 Page:2929-2947
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Sun Kang,Zhang Xiaozhen,Lao Mengyi,He Lihong,Wang Sicheng,Yang Hanshen,Xu Jian,Tang Jianghui,Hong Zhengtao,Song Jinyuan,Guo Chengxiang,Li Muchun,Liu Xinyuan,Chen Yan,Zhang Hanjia,Zhou Jingxing,Lin Jieru,Zhang Sirui,Hong Yifan,Huang Jinyan,Liang Tingbo,Bai Xueli

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference51 articles.

1. Cancer statistics, 2022;Siegel;CA. Cancer J. Clin.,2022

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA. Cancer J. Clin.,2021

3. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma;Grossberg;CA. Cancer J. Clin.,2020

4. Pancreatic cancer;Mizrahi;Lancet (London, England),2020

5. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer;Antonia;N. Engl. J. Med.,2017

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways;Experimental Hematology & Oncology;2024-04-23

2. Identifying the prognosis implication, immunotherapy response prediction value, and potential targeted compound inhibitors of integrin subunit α3 (ITGA3) in human cancers;Heliyon;2024-01

3. LINC00926 promotes progression of renal cell carcinoma via regulating miR-30a-5p/SOX4 axis and activating IFNγ-JAK2-STAT1 pathway;Cancer Letters;2023-12